Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies

PETACH TIKVA, Israel, April 16, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today announced a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute Boston, to evaluate the use of Interna's MNM technology as a delivery enhancer for targeted therapeutic modalities. Under the terms of the agreement, the collaboration will focus on integrating MNM molecules with targeting approaches to improve intracellular delivery, functional activity, and overall therapeutic performance across selected programs.